Proto-oncogene expression in HL-60 cells exposed to ara-C

Area of Science:

• Hematology
• Molecular Biology
• Cell Biology

Background:

• Cytosine-beta-D-arabinofuranoside (ara-C) is investigated for its potential to induce differentiation and maturation in hematopoietic cells.
• The HL-60 cell line is a common model for studying myeloid differentiation.

Purpose of the Study:

• To evaluate the differentiation/maturation effects of ara-C on HL-60 cells.
• To analyze morphologic changes and proto-oncogene expression patterns in response to ara-C treatment.

Main Methods:

• HL-60 cells were exposed to varying concentrations of ara-C.
• Morphologic changes were assessed using the nitroblue tetrazolium (NBT) reduction test and nonspecific esterase staining.
• Proto-oncogene expression (c-myc, c-myb, c-fos, c-fes) and histone H3 gene expression were analyzed.

Main Results:

• A concentration of 1 X 10(-7) mol/L ara-C resulted in approximately 10% of HL-60 cells becoming NBT positive after four days.
• No nonspecific esterase-positive cells were observed.
• Doses below 1 X 10(-8) mol/L had minimal effect, while doses above 1 X 10(-6) mol/L were lethal.
• Ara-C treatment did not alter proto-oncogene expression patterns typically seen with DMSO or TPA induction.
• Temporary decreases in S-phase specific and proliferation-related histone H3 gene expression were noted.

Conclusions:

• Ara-C exhibits limited differentiation-inducing effects on HL-60 cells at the tested concentrations.
• The observed changes in histone H3 gene expression may relate to spontaneous differentiation tendencies.
• In vitro models using HL-60 cells may not accurately reflect low-dose ara-C therapy outcomes due to drug inactivation and cell maturation status.